{
    "clinical_study": {
        "@rank": "129356", 
        "acronym": "CLA", 
        "arm_group": {
            "arm_group_label": "Dichloroacetate Administration", 
            "arm_group_type": "Other", 
            "description": "Patients are given the drug Dichloroacetate at a dose of 25mg/kg divided in two equal doses each day. They will take this drug for an indefinite period of time."
        }, 
        "brief_summary": {
            "textblock": "A clinical trial to evaluate the safety of Dichloroacetate in children and adults with\n      congenital lactic acidosis."
        }, 
        "brief_title": "Dichloroacetate Treatment of CLA", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Congenital Lactic Acidosis", 
        "condition_browse": {
            "mesh_term": [
                "Acidosis", 
                "Acidosis, Lactic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective is to continue evaluating the chronic safety of dichloroacetate (DCA)\n      as a potential treatment for patients with certain heretofore untreatable forms of\n      congenital lactic acidosis. Adverse events will be used to evaluate this outcome."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of congenital lactic acidosis including pyruvate dehydrogenase complex,\n\n          -  Complexes 1-4, and\n\n          -  Melas\n\n        Exclusion Criteria:\n\n          -  Intolerance to DCA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797276", 
            "org_study_id": "IRB# 420-05"
        }, 
        "intervention": {
            "arm_group_label": "Dichloroacetate Administration", 
            "description": "Subjects are given DCA 25mg/kg in a divided dose twice a day. They have EEG's done and nerve conduction studies.", 
            "intervention_name": "Dichloroacetate", 
            "intervention_type": "Drug", 
            "other_name": "DCA"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Dichloroacetate", 
            "DCA", 
            "CLA", 
            "acidosis", 
            "orphan disease"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32601"
                }, 
                "name": "University of Florida Box 200226"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Open Label", 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "Peter W. Stacpoole, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the chronic safety of oral DCA in patients with CLA, as assessed by periodic clinical biochemical and nerve conduction evaluations.", 
            "measure": "Safety and Efficacy of Dichloroacetate in Patients with Congenital Lactic Acidosis", 
            "safety_issue": "Yes", 
            "time_frame": "up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797276"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A secondary objective is to determine the genotype of the subjects. It has been determined that genotype affects the metabolism of dichloroacetate. There are slow metabolizers and fast metabolizers.  It is important to know a person's genotype for dosing purposes.  Patients will have genotypes done.", 
            "measure": "Genotype", 
            "safety_issue": "Yes", 
            "time_frame": "up to 5 years"
        }, 
        "source": "University of Florida", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institutes of Health (NIH)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2005", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}